Literature DB >> 12956022

On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication.

Bodil Svedberg1, Gunnel Backenroth-Ohsako, Kim Lützén.   

Abstract

The aim of the present study was to explore how patients experience living with long-acting depot antipsychotics given by injection. An interpretive perspective and a qualitative content analysis guided the research process and data analysis. Findings indicate that the participants understood dependency on depot treatment, as a 'safety-net' protecting from relapses and re-hospitalizations. More 'normal lives' became possible despite continuing distress from untoward effects. Participants also expressed favourable attitudes when they suffered from disabling side-effects or when they were committed to psychiatric treatment. Adherence to treatment was understood as crucial for recovering. The recovery process, related to depot treatment, was described as mainly based on the participants' experiential knowledge. This implies the need for exploring, in communication with patients, different kinds of support that might benefit their recovery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12956022     DOI: 10.1046/j.1440-0979.2003.00277.x

Source DB:  PubMed          Journal:  Int J Ment Health Nurs        ISSN: 1445-8330            Impact factor:   3.503


  11 in total

1.  Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.

Authors:  Elizabeth Bromley; Derjung M Tarn; Michael McCreary; Brian Hurley; Allison J Ober; Katherine E Watkins
Journal:  J Subst Abuse Treat       Date:  2020-04-20

2.  A hard pill to swallow: medication, empathy, and the value of collaborative recovery.

Authors:  Anne L Bizub
Journal:  Community Ment Health J       Date:  2012-09-27

3.  The importance of medication in consumer definitions of recovery from serious mental illness: a qualitative study.

Authors:  Myra Piat; Judith Sabetti; David Bloom
Journal:  Issues Ment Health Nurs       Date:  2009-08       Impact factor: 1.835

Review 4.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

5.  Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness.

Authors:  Derjung M Tarn; Kevin J Shih; Allison J Ober; Sarah B Hunter; Katherine E Watkins; Jeremy Martinez; Alanna Montero; Michael McCreary; Isabel Leamon; John Sheehe; Elizabeth Bromley
Journal:  Community Ment Health J       Date:  2022-07-29

Review 6.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 7.  Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.

Authors:  Pierre Chue; Robin Emsley
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons.

Authors:  Borah Kim; Sang-Hyuk Lee; Yen Kuang Yang; Jong-Il Park; Young-Chul Chung
Journal:  Schizophr Res Treatment       Date:  2012-08-14

Review 9.  Patient and family attitudes toward schizophrenia treatment.

Authors:  Farzin Irani; Mary Dankert; Steven J Siegel
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

10.  Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.

Authors:  Giovanni Ostuzzi; Maria Angela Mazzi; Samira Terlizzi; Federico Bertolini; Andrea Aguglia; Francesco Bartoli; Paola Bortolaso; Camilla Callegari; Mariarita Caroleo; Giuseppe Carrà; Mariangela Corbo; Armando D'Agostino; Chiara Gastaldon; Claudio Lucii; Fabio Magliocco; Giovanni Martinotti; Michela Nosé; Edoardo Giuseppe Ostinelli; Davide Papola; Marco Piero Piccinelli; Alberto Piccoli; Marianna Purgato; Tommaso Tabacchi; Giulia Turrini; Mirella Ruggeri; Corrado Barbui
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.